Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 17/20 | 0.37 |
| ▸ | PPARD | Q03181 | 16/20 | 0.37 |
| ▸ | PPARG | P37231 | 9/20 | 0.37 |
| ▸ | WRN | Q14191 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2738391 | 1.00 | PPARA (0.37) | PPARAPPARDPPARGWRN | |
| SCHEMBL2738390 | 1.00 | PPARA (0.37) | PPARAPPARDPPARGWRN | |
| SCHEMBL3956644 | 0.93 | PPARA (0.38) | PPARAPPARDPPARG | |
| SCHEMBL218478 | 0.92 | PPARA (0.36) | PPARAPPARDPPARG | |
| SCHEMBL217752 | 0.92 | PPARA (0.36) | PPARAPPARDPPARG | |
| SCHEMBL217698 | 0.91 | ERCC5 (0.38) | PPARAPPARDPPARG | |
| SCHEMBL218137 | 0.90 | PPARA (0.38) | PPARAPPARDPPARGWRN | |
| SCHEMBL2738387 | 0.89 | PPARD (0.38) | PPARAPPARDPPARG | |
| SCHEMBL219183 | 0.89 | PPARD (0.38) | PPARAPPARDPPARG | |
| SCHEMBL2738386 | 0.89 | PPARD (0.38) | PPARAPPARDPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240216312-A1 | PPAR-AGONISTS FOR USE IN THE TREATMENT OF LIVER FAILURE | GENFIT (FR) | 2024-07-04 | — | — | US | claimed |
| US-20240216313-A1 | ELAFIBRANOR DERIVATIVES AGONISTS OF PPAR FOR USE IN THE TREATMENT OF SEPSIS | GENFIT (FR) | 2024-07-04 | — | — | US | claimed |
| EP-4337184-A1 | PPAR-AGONISTS FOR USE IN THE TREATMENT OF LIVER FAILURE | Genfit (FR) | 2024-03-20 | — | — | EP | claimed |
| EP-4337185-A1 | ELAFIBRANOR DERIVATIVES AGONISTS OF PPAR FOR USE IN THE TREATMENT OF SEPSIS | Genfit (FR) | 2024-03-20 | — | — | EP | claimed |
| WO-2022238448-A1 | ELAFIBRANOR DERIVATIVES AGONISTS OF PPAR FOR USE IN THE TREATMENT OF SEPSIS | GENFIT (FR) | 2022-11-17 | — | — | WO | claimed |
| WO-2022238445-A1 | PPAR-AGONISTS FOR USE IN THE TREATMENT OF LIVER FAILURE | GENFIT (FR) | 2022-11-17 | — | — | WO | claimed |
| EP-2079722-B1 | SUBSTITUTED 3-PHENYL-1-(PHENYLTHIENYL)PROPAN-1-ONE AND 3-PHENYL-1-(PHENYLFURANYL)PROPAN-1-ONE DERIVATIVES, AND PREPARATION AND USE OF SAME | GENFIT (FR) | 2015-06-17 | — | — | EP | claimed |
| US-8088819-B2 | Derivatives of substituted 3-phenyl-1-(phenylthienyl)propan-1-ones and of 3-phenyl-1-(phenylfuranyl) propan-1-ones, preparation and use | GENFIT (FR) | 2012-01-03 | — | — | US | claimed |
| US-20100029745-A1 | DERIVATIVES OF SUBSTITUTED 3-PHENYL-1-(PHENYLTHIENYL)PROPAN-1-ONES AND OF 3-PHENYL-1-(PHENYLFURANYL) PROPAN-1-ONES, PREPARATION AND USE | GENFIT (FR) | 2010-02-04 | — | — | US | claimed |
| US-20240216312-A1 | PPAR-AGONISTS FOR USE IN THE TREATMENT OF LIVER FAILURE | GENFIT (FR) | 2024-07-04 | — | — | US | disclosed |
| US-20240216313-A1 | ELAFIBRANOR DERIVATIVES AGONISTS OF PPAR FOR USE IN THE TREATMENT OF SEPSIS | GENFIT (FR) | 2024-07-04 | — | — | US | disclosed |
| EP-4337185-A1 | ELAFIBRANOR DERIVATIVES AGONISTS OF PPAR FOR USE IN THE TREATMENT OF SEPSIS | Genfit (FR) | 2024-03-20 | — | — | EP | disclosed |
| EP-4337184-A1 | PPAR-AGONISTS FOR USE IN THE TREATMENT OF LIVER FAILURE | Genfit (FR) | 2024-03-20 | — | — | EP | disclosed |
| WO-2022238445-A1 | PPAR-AGONISTS FOR USE IN THE TREATMENT OF LIVER FAILURE | GENFIT (FR) | 2022-11-17 | — | — | WO | disclosed |
| US-8088819-B2 | Derivatives of substituted 3-phenyl-1-(phenylthienyl)propan-1-ones and of 3-phenyl-1-(phenylfuranyl) propan-1-ones, preparation and use | GENFIT (FR) | 2012-01-03 | — | — | US | disclosed |
| US-8088819-B2 | Derivatives of substituted 3-phenyl-1-(phenylthienyl)propan-1-ones and of 3-phenyl-1-(phenylfuranyl) propan-1-ones, preparation and use | GENFIT (FR) | 2012-01-03 | — | — | US | disclosed |
| US-8088819-B2 | Derivatives of substituted 3-phenyl-1-(phenylthienyl)propan-1-ones and of 3-phenyl-1-(phenylfuranyl) propan-1-ones, preparation and use | GENFIT (FR) | 2012-01-03 | — | — | US | disclosed |
| US-20100029745-A1 | DERIVATIVES OF SUBSTITUTED 3-PHENYL-1-(PHENYLTHIENYL)PROPAN-1-ONES AND OF 3-PHENYL-1-(PHENYLFURANYL) PROPAN-1-ONES, PREPARATION AND USE | GENFIT (FR) | 2010-02-04 | — | — | US | disclosed |
| US-20100029745-A1 | DERIVATIVES OF SUBSTITUTED 3-PHENYL-1-(PHENYLTHIENYL)PROPAN-1-ONES AND OF 3-PHENYL-1-(PHENYLFURANYL) PROPAN-1-ONES, PREPARATION AND USE | GENFIT (FR) | 2010-02-04 | — | — | US | disclosed |
| US-20100029745-A1 | DERIVATIVES OF SUBSTITUTED 3-PHENYL-1-(PHENYLTHIENYL)PROPAN-1-ONES AND OF 3-PHENYL-1-(PHENYLFURANYL) PROPAN-1-ONES, PREPARATION AND USE | GENFIT (FR) | 2010-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240216313-A1 | ELAFIBRANOR DERIVATIVES AGONISTS OF PPAR FOR USE IN THE TREATMENT OF SEPSIS | PPARD, PPARA, PPARG | PPARA 2/4885PPARD 1/4885PPARG 3/4885 |
| US-20240216312-A1 | PPAR-AGONISTS FOR USE IN THE TREATMENT OF LIVER FAILURE | PPARA, PPARD, FABP1 | PPARA 1/4885PPARD 2/4885PPARG 4/4885 |
| US-20100029745-A1 | DERIVATIVES OF SUBSTITUTED 3-PHENYL-1-(PHENYLTHIENYL)PROPAN-1-ONES AND OF 3-PHENYL-1-(PHENYLFURANYL) PROPAN-1-ONES, PREPARATION AND USE | TPP1, NAT1, PGC | PPARA 16/4885PPARD 4/4885PPARG 32/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.